Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF2ME4)

• Drug Name: AG-3296 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DMF2ME4

Molecule-Related Drug Atlas

Drug(s) Targeting Matrix metalloproteinase (MMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abametapir	DM2RX0I	Head and body lice	1G00.0	Approved	[3]
BLZ-100	DMFKA4G	Glioma	2A00.0	Phase 1/2	[4]
S-3304	DMCBQTF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
ABT-518	DMA2RM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]
D-1927	DM5D8JW	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[7]
S-3536	DMZYRI3	Osteoarthritis	FA00-FA05	Discontinued in Phase 1	[8]
BB-2983	DMYK8OG	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[9]
ONO-4817	DMKRVUN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[10]
DFD-11	DMHXVN1	Head and body lice	1G00.0	Application submitted	[11]
D-9120	DMHNZ1P	Inflammatory bowel disease	DD72	Terminated	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Matrix metalloproteinase (MMP)	TT1GHVO	NOUNIPROTAC	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007472)
• [2] US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [4] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [5] Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
• [6] Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
• [7] Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
• [8] CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
• [9] Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
• [10] ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.